INSIGHTEC has announced the US Food and Drug Administration (FDA) has approved its updated Exablate system to treat symptomatic uterine fibroids.

InsightecLogo 101011 200

The company earned FDA approval to treat uterine fibroids in 2004, but the recent ruling will enable physicians to utilize a more advanced version of the technology. 

INSIGHTEC's announcement also notes an expanded labeling for its product, as patients no longer need to be family complete to be considered for the treatment. This change allows younger women who plan to conceive in the future to take advantage of this uterus-sparing procedure.

“The combination of INSIGHTEC’s next generation system and the expansion of our labeling, brings new benefits to treating physicians and women alike, as we can now serve a larger cohort of patients," says Ramya Singh, the company's Vice President of the Americas.

Read the Release >

 

 

The Focused Ultrasound Foundation Newsletter

Our newsletter delivers updates for clinicians, researchers and patients. Sign up and stay on top of the rapid advancements of this innovative medical technology.

Sign Up  Read the Latest Issue

Read The Tumor  by John Grisham

From John Grisham, comes a story where today’s medical fiction could become tomorrow’s lifesaving reality.

Download a Free eBook or Audiobook

Contact Details

Call Us
434.220.4993
Find Us
Focused Ultrasound Foundation
1230 Cedars Court, Suite 206 Charlottesville, VA 22903
Email